See more : Luxshare Precision Industry Co., Ltd. (002475.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Galmed Pharmaceuticals Ltd. (GLMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galmed Pharmaceuticals Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- KebNi AB (publ) (KEBNI-B.ST) Income Statement Analysis – Financial Results
- Cellectis S.A. (ALCLS.PA) Income Statement Analysis – Financial Results
- Synel M.L.L Payway Ltd (SNEL.TA) Income Statement Analysis – Financial Results
- Vitrolife AB (publ) (VITR.ST) Income Statement Analysis – Financial Results
- Alla Public Company Limited (ALLA.BK) Income Statement Analysis – Financial Results
Galmed Pharmaceuticals Ltd. (GLMD)
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.04M | 1.09M | 467.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 31.00K | 35.00K | 42.00K | 39.00K | 35.00K | 0.00 | 0.00 | 0.00 | 50.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -31.00K | -35.00K | -42.00K | -39.00K | -35.00K | 2.04M | 1.09M | 467.00K | -50.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.57M | 13.00M | 27.22M | 26.08M | 18.18M | 8.31M | 9.65M | 14.27M | 7.63M | 6.66M | 7.21M | 2.44M |
| General & Administrative | 3.72M | 4.66M | 5.66M | 4.13M | 4.20M | 4.44M | 3.80M | 3.08M | 3.25M | 2.48M | 7.36M | 694.00K |
| Selling & Marketing | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.92M | 4.66M | 5.66M | 4.13M | 4.20M | 4.44M | 3.80M | 3.08M | 3.25M | 2.48M | 7.36M | 694.00K |
| Other Expenses | -14.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 0.00 |
| Operating Expenses | -7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.88M | 9.14M | 14.56M | 3.14M |
| Cost & Expenses | -7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.88M | 9.14M | 14.56M | 3.14M |
| Interest Income | 375.00K | 297.00K | 562.00K | 1.19M | 1.92M | 959.00K | 65.00K | 35.00K | 253.00K | 40.00K | 0.00 | 6.00 |
| Interest Expense | 11.00K | 215.00K | 43.00K | 31.00K | 33.00K | 42.00K | 49.00K | 67.00K | 0.00 | 0.00 | 34.00K | 0.00 |
| Depreciation & Amortization | 31.00K | 35.00K | 42.00K | 39.00K | 35.00K | 387.00K | 239.00K | 169.00K | 50.00K | 9.00K | 4.00K | 5.00K |
| EBITDA | -6.87M | -17.62M | -32.84M | -30.17M | -22.34M | -10.33M | -12.13M | -16.71M | -10.83M | -9.13M | -14.57M | -3.13K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -507.61% | -1,117.51% | -3,578.80% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 7.49M | -17.65M | -32.88M | -30.21M | -22.38M | -10.72M | -12.36M | -16.88M | -10.88M | -9.14M | -14.57M | -3.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -525.76% | -1,139.54% | -3,614.99% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -14.40M | -215.00K | 414.00K | 1.44M | 1.92M | 934.00K | 65.00K | 35.00K | 253.00K | 40.00K | -2.92M | -6.00K |
| Income Before Tax | -6.91M | -17.87M | -32.47M | -28.77M | -20.46M | -9.78M | -12.30M | -16.85M | -10.62M | -9.10M | -17.48M | -3.14M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -479.93% | -1,133.55% | -3,607.49% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 705.00K | -519.00K | -1.16M | -1.92M | 75.00K | 12.36M | 106.00K | 21.24M | 1.00K | 1.00K | 6.00K |
| Net Income | -6.91M | -18.57M | -31.95M | -27.61M | -18.54M | -9.86M | -12.30M | -16.95M | -10.62M | -9.10M | -17.49M | -3.15M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -483.61% | -1,133.55% | -3,630.19% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -30.05 | -11.08 | -19.48 | -19.46 | -13.17 | -8.15 | -14.77 | -22.36 | -14.35 | -13.23 | -24.57 | -9.32 |
| EPS Diluted | -29.95 | -11.08 | -19.48 | -19.46 | -13.17 | -8.15 | -14.77 | -22.36 | -14.35 | -13.23 | -24.57 | -9.32 |
| Weighted Avg Shares Out | 230.00K | 1.68M | 1.64M | 1.42M | 1.41M | 1.21M | 832.49K | 758.31K | 740.03K | 688.25K | 711.66K | 337.96K |
| Weighted Avg Shares Out (Dil) | 230.79K | 1.68M | 1.64M | 1.42M | 1.41M | 1.21M | 832.49K | 758.31K | 740.03K | 688.25K | 711.66K | 337.96K |
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Galmed Pharma Surges 400%: What's Behind the Explosion?
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
Source: https://incomestatements.info
Category: Stock Reports